673 related articles for article (PubMed ID: 15150417)
1. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
Bosch BJ; Martina BE; Van Der Zee R; Lepault J; Haijema BJ; Versluis C; Heck AJ; De Groot R; Osterhaus AD; Rottier PJ
Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8455-60. PubMed ID: 15150417
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus.
Xu Y; Zhu J; Liu Y; Lou Z; Yuan F; Liu Y; Cole DK; Ni L; Su N; Qin L; Li X; Bai Z; Bell JI; Pang H; Tien P; Gao GF; Rao Z
Biochemistry; 2004 Nov; 43(44):14064-71. PubMed ID: 15518555
[TBL] [Abstract][Full Text] [Related]
3. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
Liu S; Xiao G; Chen Y; He Y; Niu J; Escalante CR; Xiong H; Farmar J; Debnath AK; Tien P; Jiang S
Lancet; 2004 Mar; 363(9413):938-47. PubMed ID: 15043961
[TBL] [Abstract][Full Text] [Related]
4. Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.
Liu IJ; Kao CL; Hsieh SC; Wey MT; Kan LS; Wang WK
Antiviral Res; 2009 Jan; 81(1):82-7. PubMed ID: 18983873
[TBL] [Abstract][Full Text] [Related]
5. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.
Yuan K; Yi L; Chen J; Qu X; Qing T; Rao X; Jiang P; Hu J; Xiong Z; Nie Y; Shi X; Wang W; Ling C; Yin X; Fan K; Lai L; Ding M; Deng H
Biochem Biophys Res Commun; 2004 Jul; 319(3):746-52. PubMed ID: 15184046
[TBL] [Abstract][Full Text] [Related]
6. Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state.
Hakansson-McReynolds S; Jiang S; Rong L; Caffrey M
J Biol Chem; 2006 Apr; 281(17):11965-71. PubMed ID: 16507566
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core.
Xu Y; Lou Z; Liu Y; Pang H; Tien P; Gao GF; Rao Z
J Biol Chem; 2004 Nov; 279(47):49414-9. PubMed ID: 15345712
[TBL] [Abstract][Full Text] [Related]
8. Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein.
Supekar VM; Bruckmann C; Ingallinella P; Bianchi E; Pessi A; Carfí A
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):17958-63. PubMed ID: 15604146
[TBL] [Abstract][Full Text] [Related]
9. Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein.
Duquerroy S; Vigouroux A; Rottier PJ; Rey FA; Bosch BJ
Virology; 2005 May; 335(2):276-85. PubMed ID: 15840526
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core.
Xu Y; Liu Y; Lou Z; Qin L; Li X; Bai Z; Pang H; Tien P; Gao GF; Rao Z
J Biol Chem; 2004 Jul; 279(29):30514-22. PubMed ID: 15123674
[TBL] [Abstract][Full Text] [Related]
11. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.
Bosch BJ; van der Zee R; de Haan CA; Rottier PJ
J Virol; 2003 Aug; 77(16):8801-11. PubMed ID: 12885899
[TBL] [Abstract][Full Text] [Related]
12. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
13. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism.
Guillén J; Pérez-Berná AJ; Moreno MR; Villalaín J
J Virol; 2005 Feb; 79(3):1743-52. PubMed ID: 15650199
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion.
Petit CM; Melancon JM; Chouljenko VN; Colgrove R; Farzan M; Knipe DM; Kousoulas KG
Virology; 2005 Oct; 341(2):215-30. PubMed ID: 16099010
[TBL] [Abstract][Full Text] [Related]
15. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus.
Chan WE; Chuang CK; Yeh SH; Chang MS; Chen SS
J Virol; 2006 Apr; 80(7):3225-37. PubMed ID: 16537590
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus.
Ingallinella P; Bianchi E; Finotto M; Cantoni G; Eckert DM; Supekar VM; Bruckmann C; Carfi A; Pessi A
Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8709-14. PubMed ID: 15161975
[TBL] [Abstract][Full Text] [Related]
19. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
Ni L; Zhu J; Zhang J; Yan M; Gao GF; Tien P
Biochem Biophys Res Commun; 2005 Apr; 330(1):39-45. PubMed ID: 15781229
[TBL] [Abstract][Full Text] [Related]
20. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors.
Zhu J; Xiao G; Xu Y; Yuan F; Zheng C; Liu Y; Yan H; Cole DK; Bell JI; Rao Z; Tien P; Gao GF
Biochem Biophys Res Commun; 2004 Jun; 319(1):283-8. PubMed ID: 15158473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
